From Financial Modeling Prep: 2025-05-12 16:00:00

GRAIL, Inc. (NASDAQ:GRAL) offers the Galleri test for early cancer detection, screening over 50 types of cancer for individuals over 50. The company’s stock price target remains stable at $32, reflecting analysts’ positive outlook. GRAIL’s financial performance boasts a 45% year-over-year increase in U.S. Galleri revenue, reaching $108.6 million, with a cash position of $767 million extending its financial runway into 2028. Investors should monitor GRAIL’s progress, including potential Medicare reimbursement for the Galleri test and bipartisan legislation that could impact revenue. Despite risks like pending FDA approval and reimbursement delays, GRAIL’s strategic partnerships and commercial growth position it for success in the biotechnology and healthcare sectors.



Read more at Financial Modeling Prep:: GRAIL, Inc. (NASDAQ:GRAL) – A Leader in Early Canc…